Healthcare and Life Science
Antibodies.com expands UK headquarters with new 5x larger facilities in Cambridge to accommodate rapid growth
Cambridge, UK, 04 August 2025: Antibodies.com, a trusted provider of high-quality biological reagents for life science researchers, today announced the expansion of its UK headquarters with a move to Cambridge Technopark to accommodate the Company’s rapid growth. The new 5000 sq. ...
Team Consulting and inclusive surgical devices at Royal College of Surgeons of England event
Team Consulting are attending the Women at the Cutting Edge event hosted by the Royal College of Surgeons of England, in partnership with the RCS England I-Hub and Women in Surgery (WinS) group, on Friday 17th October 2025 at the Birmingham Repertory Theatre. Team's Senior FEI Strategy...
Radiotherapy and surgical ablation technologies for cancer treatment
Radiotherapy, or radiation ablation, has evolved significantly since its inception. Ongoing technological advancements have the potential to position radiotherapy as a first-line “surgical” treatment for solid tumours by enhancing its precision and efficacy. Further advancements in real...
How surrogate models enhance medical device optimisation
Design optimisation is a fundamental step in developing innovative and efficient medical devices. Before committing to manufacturing prototypes, simulations and models are developed to indicate the expected performance of the medical device design. They offer great precision however,...
Preventing patient hospitalisation through better stratification and timely intervention
In the realm of healthcare, patient hospitalisation can often be avoided through timely intervention and appropriate medication management. One powerful strategy to achieve this is patient stratification—classifying patients into different groups based on their vulnerability to hos...
Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidateCentauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026CARB-X’s addition...
Exonate plans ‘CLEAR-DE’ Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedemaPhase IIb trial to investigate efficacy in NPDR patients to commence in Q1 2026Cambridge, UK, 29 July 2025: E...
PhoreMost appoints Dr Adam Gilbert to Scientific Advisory Board
Expert in targeted protein degradation and drug discovery will support development of the Company’s portfolio of novel small molecule degraders ...
RAEN & Shine
Authenticity is key for the latest brand to join Taank's stable. RAEN’s designers live and breathe ocean adventures and have a deep respect for nature. They share this reverence through their beautiful 'modern classic' frames that emit the warmth and energy of SoCal while remaining root...
The world’s most precise eye test: Rodenstock DNEye® Scanner
Taank is the proud new owner of Rodenstock’s high-precision DNEye® Scanner, which will be used during every eye exam. This revolutionary scanner is the first of its kind to map each eye with absolute precision. Find out more about what it does and why we love it. ...